



December 13, 2023

We are pleased to inform you that today we announced positive healthy volunteer data from the Phase 1/2 EXPLORE44™ study evaluating AOC 1044 for the treatment of Duchenne muscular dystrophy mutations amenable to exon 44 skipping (DMD44).

AOC 1044 was well tolerated and delivered unprecedented concentrations of phosphorodiamidate morpholino oligomers (PMO) in skeletal muscle. AOC 1044 produced statistically significant exon 44 skipping compared to placebo of up to 1.5% in healthy volunteers after a single dose of 10 mg/kg and increased exon skipping in all participants. This is the first data readout from the EXPLORE44 trial, and we are excited to share these data with you and the broader DMD community.

You can view our full press release of today's DMD news on our corporate website (<https://aviditybiosciences.investorroom.com/news-releases>).

### **Phase 1/2 EXPLORE44 Healthy Volunteer Data**

- AOC 1044 delivered unprecedented, dose-dependent increases in PMO concentrations in skeletal muscle following a single dose of 5 mg/kg or 10 mg/kg, providing up to 50-times greater concentrations of PMO in skeletal muscle when compared to a single dose of peptide conjugated PMOs in healthy volunteers.
- AOC 1044 produced statistically significant exon 44 skipping compared to placebo of up to 1.5% in healthy volunteers after a single dose of 10 mg/kg AOC 1044 at Day 29. AOC 1044 increased exon skipping in all participants.
- AOC 1044 was well tolerated in healthy volunteers. All treatment-emergent adverse events in participants dosed with AOC 1044 were mild to moderate. There were no symptomatic hemoglobin changes, no hypomagnesemia and no renal events.

We are excited by these data from healthy volunteers as we continue to enroll people living with DMD44 into our Phase 1/2 EXPLORE44 study. A first look at data from participants with Duchenne is planned in the second half of 2024.

We remain steadfast in our commitment to advance meaningful therapies for the muscular dystrophy community, and we want to thank each participant in the study, their families, our advocacy partners as well as the investigators and their teams for their time, commitment, and continued contributions. We share the urgency for a treatment for people living with DMD44 and we remain hopeful about the potential of AOC 1044.

To learn more about the EXPLORE44 trial, please visit [www.explore44study.com](http://www.explore44study.com). We encourage you to contact your doctor if you have any questions about AOC 1044 or the EXPLORE44 trial.

Sincerely,

The Avidity Team